Rescue Pacing for Congenital Complete Heart Block
This project aims to develop a gene therapy using adenoviral vectors to increase heart rates in fetuses with congenital complete heart block, enabling safe pacemaker implantation post-birth.
Projectdetails
Introduction
Congenital heart block is the most commonly observed type of foetal bradycardia, occurring in one in 15,000 live births. A significant subset of foetuses develops towards congenital complete heart block (CCHB), i.e., complete failure of the electrical excitation wavefront to be conducted over the atrioventricular (AV) node.
Significance of CCHB
CCHB is the most severe and life-threatening cardiac arrhythmia in utero. Current medicinal treatments cannot significantly alter the cause of CCHB and therapeutic attempts at human foetal cardiac pacing have been unsuccessful.
Project Objective
For CCHB patients at high risk for life-threatening disease progression and death due to severe bradycardia before 34 weeks of gestation, this project develops a gene therapy medicinal product (GTMP) that is based on adenoviral vector-mediated ion channel overexpression.
Expected Outcomes
The goal is to transiently increase heart rates over the course of several months. When successful, such a GTMP would rescue these patients and allow for permanent pacemaker implantation in the first months after birth.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 150.000 |
Totale projectbegroting | € 150.000 |
Tijdlijn
Startdatum | 1-8-2022 |
Einddatum | 31-1-2024 |
Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- STICHTING AMSTERDAM UMCpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
MANUNKIND: Determinants and Dynamics of Collaborative ExploitationThis project aims to develop a game theoretic framework to analyze the psychological and strategic dynamics of collaborative exploitation, informing policies to combat modern slavery. | ERC STG | € 1.497.749 | 2022 | Details |
Elucidating the phenotypic convergence of proliferation reduction under growth-induced pressureThe UnderPressure project aims to investigate how mechanical constraints from 3D crowding affect cell proliferation and signaling in various organisms, with potential applications in reducing cancer chemoresistance. | ERC STG | € 1.498.280 | 2022 | Details |
Uncovering the mechanisms of action of an antiviral bacteriumThis project aims to uncover the mechanisms behind Wolbachia's antiviral protection in insects and develop tools for studying symbiont gene function. | ERC STG | € 1.500.000 | 2023 | Details |
The Ethics of Loneliness and SociabilityThis project aims to develop a normative theory of loneliness by analyzing ethical responsibilities of individuals and societies to prevent and alleviate loneliness, establishing a new philosophical sub-field. | ERC STG | € 1.025.860 | 2023 | Details |
MANUNKIND: Determinants and Dynamics of Collaborative Exploitation
This project aims to develop a game theoretic framework to analyze the psychological and strategic dynamics of collaborative exploitation, informing policies to combat modern slavery.
Elucidating the phenotypic convergence of proliferation reduction under growth-induced pressure
The UnderPressure project aims to investigate how mechanical constraints from 3D crowding affect cell proliferation and signaling in various organisms, with potential applications in reducing cancer chemoresistance.
Uncovering the mechanisms of action of an antiviral bacterium
This project aims to uncover the mechanisms behind Wolbachia's antiviral protection in insects and develop tools for studying symbiont gene function.
The Ethics of Loneliness and Sociability
This project aims to develop a normative theory of loneliness by analyzing ethical responsibilities of individuals and societies to prevent and alleviate loneliness, establishing a new philosophical sub-field.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Transcription Factor Gene Therapy for BradyarrhythmiasPacingCure's TRACTION project aims to optimize and validate BradyTx-01, a gene therapy for cardiac pacing dysfunctions, ensuring safety, efficacy, and a pathway to commercialization. | EIC Transition | € 2.499.968 | 2023 | Details |
Reversible and irreversible cardiac electroporation: Establishing the fundamentals to advance cardiac treatmentsThis project aims to understand cardiac electroporation mechanisms to develop methods for effective irreversible and reversible treatments for atrial fibrillation and ischemic heart disease. | ERC STG | € 1.500.000 | 2024 | Details |
Cardiogenomics meets Artificial Intelligence: a step forward in arrhythmogenic cardiomyopathy diagnosis and treatmentThe project aims to integrate genomics, proteomics, and structural analyses to clarify genotype-phenotype relationships in arrhythmogenic cardiomyopathy, paving the way for novel therapies. | EIC Pathfinder | € 3.740.868 | 2023 | Details |
NaV1.5 regulation fine-tuning as a therapy for cardiac Conduction and Arrhythmic diseases at Risk of suddEn DeathThe NaV1.5-CARED consortium aims to develop innovative therapies for cardiac arrhythmias by identifying genetic factors and therapeutic targets to restore NaV1.5 function and personalize risk assessment. | EIC Pathfinder | € 4.546.205 | 2023 | Details |
Transcription Factor Gene Therapy for Bradyarrhythmias
PacingCure's TRACTION project aims to optimize and validate BradyTx-01, a gene therapy for cardiac pacing dysfunctions, ensuring safety, efficacy, and a pathway to commercialization.
Reversible and irreversible cardiac electroporation: Establishing the fundamentals to advance cardiac treatments
This project aims to understand cardiac electroporation mechanisms to develop methods for effective irreversible and reversible treatments for atrial fibrillation and ischemic heart disease.
Cardiogenomics meets Artificial Intelligence: a step forward in arrhythmogenic cardiomyopathy diagnosis and treatment
The project aims to integrate genomics, proteomics, and structural analyses to clarify genotype-phenotype relationships in arrhythmogenic cardiomyopathy, paving the way for novel therapies.
NaV1.5 regulation fine-tuning as a therapy for cardiac Conduction and Arrhythmic diseases at Risk of suddEn Death
The NaV1.5-CARED consortium aims to develop innovative therapies for cardiac arrhythmias by identifying genetic factors and therapeutic targets to restore NaV1.5 function and personalize risk assessment.